Security key
29251M106
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)
CUSIP: 29251M106
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Total 13F shares
- 18,415,589
- Total 13F value
- $139,218,163
- Share change
- -201,826
- Put/Call ratio
- 0%
- SEC-reported price per share
- $7.56
- Number of holders
- 103
- Value change
- -$1,130,233
- Number of buys
- 46
- Number of sells
- 58
- Shares outstanding
- 29,057,686
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
103
Top holders
10
ENTA full security history
Ownership snapshot
Full 13F holder table
ENANTA PHARMACEUTICALS INC SEC filings
ENANTA PHARMACEUTICALS INC company facts
Broader feeds
Ownership snapshot
Top reported holders of ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
13D/G
Lead comparable stake: 7.8%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 7.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
7.8%
Ph.D. Jay R. Luly
7.7%
FARALLON CAPITAL MANAGEMENT, L.L.C.
7.3%
Krensavage Asset Management, LLC
7.3%
VANGUARD GROUP INC
6.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
7.8%
from 13D/G
|
$11,143,054
2,018,669 shares
|
— | 31 Mar 2025 |
| Ph.D. Jay R. Luly |
13D/G
Jay R. Luly, Ph.D.
|
7.7%
|
$9,659,503
1,703,616 shares
|
$0 | 12 Feb 2025 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
7.3%
|
$11,714,886
2,122,262 shares
|
— | 31 Mar 2025 |
| Krensavage Asset Management, LLC |
13F
Company
|
7.3%
|
$11,684,000
2,116,586 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
6.9%
|
$11,081,031
2,007,433 shares
|
— | 31 Mar 2025 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
4.6%
|
$7,435,065
1,346,932 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
103
Shares
18,415,589
Rows available
103
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
108
Q2 2025 holders
103
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|